Regeneron Pharmaceuticals, ConforMIS, Cryolife Stocks Moving Today

U.S. stocks are slightly lower this afternoon. Among specific equities in focus are healthcare stocks Regeneron Pharmaceuticals Inc (NASDAQ:REGN), ConforMIS Inc (NASDAQ:CFMS), and Cryolife Inc (NYSE:CRY). Here's a quick look at what's moving shares of REGN, CFMS, and CRY.

Political Uncertainty Could Hit Regeneron 

REGN is down 2.9% at $373.02, after Goldman Sachs downgraded the stock to "neutral" from "buy," while removing it from the "Americas Buy" list. The brokerage firm added, "We expect policy uncertainty to remain an overhang on biopharma stocks given the rapidly evolving political environment." It's been an up-and-down year for Regeneron Pharmaceuticals Inc, which is now trading near the middle of its 12-month range. Still, the majority of analysts agree with Goldman Sachs, with 11 of 19 brokerage firms handing out "hold" ratings. 

ConforMIS Continues to Sell Off After Earnings

CFMS is also tanking, after the company's disappointing fourth-quarter results and full-year outlook. At last check, the shares were down 35% at $5.56 -- on the short-sale restricted (SSR) list -- far below their annual highs near $14 from April. Meanwhile, Canaccord Genuity cut its rating to "hold," while dropping its price target to $7 from $12, and B. Riley lowered its price target to $7.50 from $13. More bearish analyst attention could be on the way, however, since four out of six brokerage firms consider ConforMIS Inc a "strong buy," with no "sell" ratings on the books. 

Lackluster Forecast Sinks Cryolife

Rounding out this list of losers, CRY is near the bottom of the New York Stock Exchange today. After being halted out of the gate, the stock was last seen down 16.9% at $16.25 -- and also SSR -- due to the company's lower-than-expected full-year forecast. The stock is now on pace for its lowest close since early September, so it'll be interesting to see if bullish analysts adjust their positions. For instance, all but one covering brokerage firm considers Cryolife Inc a "strong buy."